EMA recommends stopping sale of GSK’s blood cancer drug in EU
The European Medicines Agency has recommended the stoppage of conditional marketing authorisation for GSK’s Blenrep (belantamab mafodotin), a medicine used to treat cancer of.
Drugs
Health
Pharma